Simplex Trading’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Simplex Trading’s Portfolio TCRR Stock Details TCRR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-147,000	Closed	-$146K	–	10582
2022 Q4	$146K	Sell	147,000 -12,300	-8%	-$16.6K	﹤0.01%	4631
2022 Q3	$286K	Buy	159,300 +16,100	+11%	+$46.7K	﹤0.01%	4142
2022 Q2	$415K	Buy	143,200 +140,600	+5,408%	+$347K	﹤0.01%	3685
2022 Q1	$7K	Sell	2,600 -1,000	-28%	-$3.15K	﹤0.01%	9240
2021 Q4	$16K	Buy	+3,600	New	+$22.5K	﹤0.01%	8645
2021 Q2	–	Sell	-24	Closed	-$52K	–	10925
2021 Q1	$52K	Sell	24 -12	-33%	-$327	﹤0.01%	6582
2020 Q4	$111K	Sell	36 -2	-5%	-$51	﹤0.01%	5354
2020 Q3	$77K	Buy	+38	New	+$667	﹤0.01%	5187

Simplex Trading's TCRR Position: Q2 2023 in Review

Simplex Trading sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 1,444 shares — an estimated $2K sold.

Simplex Trading first reported a position in TCRR in Q1 2020 and held it in 7 quarters. The position peaked at $40K in Q4 2020. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.

Simplex Trading reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Simplex Trading sold 1,444 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $2K.
Simplex Trading first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2020 and held it in 7 quarters.
Simplex Trading's TCR2 Therapeutics Inc. Common Stock position peaked at $40K in Q4 2020.
0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.

Based on Simplex Trading's 13F filing for Q2 2023, filed 4 Aug 2023.